Abstract
Regional anesthesia means the interruption of impulse conduction in the nerves using specific, reversibly acting drugs (local anesthetics). The indications for regional anesthesia include clinical anesthesia, obstetrics, postoperative analgesia, and pain therapy. Before conducting regional anesthesia, the same type of assessment of the patient should be carried out as for general anesthesia. To ensure cooperation, the patient should be given simple, short information about the aim of the block, its technical performance, possible or probable paresthesia and their significance, as well as the potential complications. The patient information session and consent, either verbal or written, should be documented. It is important that a number of safety measures are taken to ensure the most suitable regional anesthesia technique is performed for the correct patient. The comprehensive record and checklist has pertinent information including purpose of the block, position and approach, type of local anesthetics used, and complications that might arise. Such standardized recommendations are useful for the purpose of medicolegal documentation and conducting retrospective studies on complications. In addition, the detailed pharmacology of local anesthetic and the use of regional anesthesia in patient on anticoagulants or antiplatelet agents will also be reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Notes
- 1.
The antiplatelet effect is not immediate. Neuraxial catheters may be maintained for 1–2 days provided a loading dose of the antiplatelet agent is not administered.
- 2.
In patients with high risk of thromboembolic events or for trial of SCS: a 5 day discontinuation is recommended (e.g., a “bridge” therapy with low molecular weight heparin). After an intervention, the usual daily dose (75 mg) of clopidogrel can be started 12 h later.
- 3.
Risk-benefit assessment: higher bleeding risk profiles, concomitant antiplatelet medications, advanced patient age, advanced liver or renal disease, or prior history of abnormal bleeding exist.
- 4.
Neuraxial catheters should not be maintained with prasugrel or ticagrelor because of the rapid onset. Thienopyridine therapy may be resumed immediately after needle placement/ catheter removal, provided a loading dose of the drugs is not administered. If loading dose is administered, ASRA suggests a time interval of 6 h between catheter removal and administration.
- 5.
Risk-benefit assessment: higher bleeding risk profiles, concomitant antiplatelet medications, advanced patient age, advanced liver or renal disease, or prior history of abnormal bleeding exist.
- 6.
Although the LMWHs constitute a relatively homogenous pharmacological group, the most studied and referenced drug is Enoxaparin; there are different commercial preparations on the market that share common characteristics but that also possess different clinical and pharmacological properties and must be regarded as similar but not equal drugs.
- 7.
The safety of indwelling neuraxial catheters in patients receiving doses >5000 U or > 15,000 U of UFH/day has not been established. The risk and benefits be assessed on an individual basis (neurologic monitoring).
- 8.
Enoxaparin 30 mg BID or 40 mg /once d.
- 9.
Enoxaparin 1 mg/kg every 12 h; Dalteparin 120 U/kg every 12 h, 200 U/kg every 12 h; Tanzaparin 175 U/ kg day.
- 10.
Prophylactic dose for joint replacement.
- 11.
Risk reduction or treatment for VTE or PE; RA-regional anesthesia procedure including manipulation or removal of catheter.
- 12.
72 h (3 days) (CrCl ≥80 mL/min); 96 h (4 days) (CrCl 50–79 mL/min); 120 h (5 days) (CrCl 30–49 mL/min) (ASRA).
Suggested Reading
Ahmed I, Gertner E. Safety of arthrocentesis and joint injection in patients recieving anticoagulation at therapeutic levels. Am J Med. 2012;125:265–9.
Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangreol: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50:27–35.
Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology. 1978;51:285–7.
Auroy Y, Narchi P, Messiah A, et al. Serious complications related to regional anesthesia: results of a prospective survey in France. Anesthesiology. 1997;87:479–86.
Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res. 1985;39:631–6.
Baranowski AP, De Courcey J, Bonelle E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. J Pain Symptom Manage. 1999;17(6):429–33.
Benedek ICH, Joshi AS, Pieniaszek HJ, King SY, et al. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol. 1995;35:1181–6.
Benzon HT. Regional anesthesia in the anticoagulated patient. In: Hadzic A, editor. Peripheral nerve blocks. 2nd ed. New York: Mc Graw Hill; 2012. p. 107–13.
Benzon HT, Avram J, Green D, et al. New oral anticoagulants and regional anesthesia. Br J Anesth. 2013;111:i96–i113.
Bonica JJ. Biology, pathophysiology, and treatment of acute pain. In: Lipton S, Miles J, editors. Persistent pain, vol. 5. New York: Grune & Stratton; 1985. p. 1–32.
Bonica JJ, Buckley PF. Regional analgesia with local anesthetics. In: Bonica JJ, editor. Management of pain. 2nd ed. Philadelphia: Lea & Febiger; 1990.
Borchard U, Niesel HC. Grundlagen der Pharmakologie der Lokalanästhetika. In: Niesel HC, editor. Regionalanästhesie, Lokalanästhesie, Regionale Schmerztherapie. Stuttgart: Georg Thieme; 1994.
Bradlow BA, Chetty N. Dosage frequencyfor supression of platelet function by low dose aspirin therapy. Thromb Res. 1982;27:99–110.
Braid BP, Scott DB. The systemic absorptionof local analgesic drugs. Br J Anesth. 1965;37:394.
Brandt JT, Payne CD, Wiviott CD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153:66.e9–e16.
Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978;61:314–9.
Butterworth JF, Strichartz GR. The molecular mechanisms by which local anesthetics produce impulse blockade:a review. Anesthesiology. 1990;72:711–34.
Campbell JN, Raja SN, Cohen RH, Manning D, Khan A, Meyer RA. Peripheral neural mechanisms of nociception. In: Wall PD, Melzack R, editors. Textbook of pain. 2nd ed. Edinburgh: Churchill Livingstone; 1989.
Campion FX. Good medical records can be strongest malpractice defense. In: Grand rounds on medical malpractice. Chicago: American Medical Association; 1990.
Catterall W. Cellular and molecular biology of voltage-gated sodium channels. Physiol Rev. 1992;72:S15–48.
Convay R, O’Shea FD, Cunnane G, et al. Safety of joint and soft tissue injections in patients on warfarin anticoagulation. Clin Rheumatol. 2013;32:1811–24.
Covino BG. Toxicity and systemic effects of local anesthetic agents. In: Stricharzt GR, editor. Handbook of experimental pharmacology, vol. 81. Berlin: Springer; 1987. p. 187–212.
Davies NM, Anderson KE. Clinical pharmacocinetics of naproxen. Clin Pharmacokinet. 1997;32:268–93.
Dawes PJ, O’Keefe L, Adcock S. Informed consent: Using structured interview changes patients attitudes towards informed consent. J Laryngol Otol. 1993;107:775–9.
Devit JH, Rapanos T, Kurreck M, et al. The anesthetic record: accuracy and completeness. Can J Anaesth. 1999;46:122–8.
Devor M. Central changes mediating neuropathic pain. In: Dubner R, Gebhart GF, Bond MR, editors. Proceedings of the Vth world congress on pain. Pain research and clinical management. Amsterdam: Elsevier; 1988. p. 7.
Di Gregorio G, Neal MJ, Rosenquist RW, Weinberg LG. Clinical presentation of local anesthetic systemic toxicity. A review of published cases, 1979 to 2009. Reg Anesth Pain Med. 2010;35:181–7.
Di Nisio M, Middeldrop S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028–40.
Enders S, Shufelt A, Bogduk N. The risks of continuing or discontinuing anticoagulants for patients undergoing common interventional pain procedures. Pain Med. 2017;18:403–9.
Feldman JM. Do anesthesia information systems increase malpractice exsposure? Result of a survey. Anesth Analg. 2004;99:840–3.
Fields HL, Basbaum AI. Central nervous system mechanisms of pain modulation. In: Wall PD, Melzack R, editors. Textbook of pain. 3rd ed. London: Churchill Livingstone; 1994. p. 243–57.
Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor. Xa inhibitor Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013a;75:476–87.
Frost C, Nepal S, Wang J, et al. Safety pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013b;76:776–86.
Gadsen J. Local anesthetics: clinical pharmacology and rational selection. In: Hadzic A, editor. Peripheral nerve blocks and anatomy for ultrasound-guided regional anesthesia. New York: McGraw Hill; 2012. p. 30–40.
Gadsen J, Hadzic A, Gandhi K, et al. The effect of mixing 1.5% mepivacaine and 0.5% bupivacaine on duration of analgesia and latency of block onset in ultrasound-guided interscalene block. Anesth Analg. 2011;112:471–6.
Galer BS, Rowbotham MC, Perander J. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533–8.
Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol. 2003;43(2):111–7.
Gerancher JC. Documentation of regional anesthesia procedures. In: Hadzic A, editor. Textbook of regional anesthesia and acute pain management. New York: McGraw Hill; 2007. p. 1164–70.
Gerancher JC, Viscusi ER, Liguori GA, et al. Development of standardized peripheral nerve block procedure note form. Reg Anesth Pain Med. 2005;30(1):67–71.
Gogarten W, Vandermeulen E, van Aken H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27:999–1015.
Graf BM, Martin E, Bosnjak ZJ, et al. Stereospecific effect of bupivacaine isomers on atrioventricular conduction in the isolated perfused guinea pig heart. Anesthesiology. 1997;86:410–9.
Groban L, Deal DD, Vernon JC, James RL, Butterworth J. Cardiac resuscitation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine in anesthetized dogs. Anesth Analg. 2001;92:37–43.
Guay J. The epidural test dose: a Review. Anesth Analg. 2006;102:921–9.
Gurbel PA, Bliden KP, Butler K, et al. Randomized double–blind assessment of the ONSET and OFFSET oft he antiplatelet effects of ticagrelor versus clopidogrell in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–85.
Gy L, Endoxaban AG. A focussed review of ist clinical pharmacology. Eur Heart J. 2014;35:1884–5.
Hadzic A, Vloka JD. Equipment and patient monitoring in regional anesthesia. In: Hadzic A, Vloka JD, editors. Peripheral nerve blocks: principles and practice. New York: McGraw-Hill; 2004. p. 29–41.
Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and managemant in the perioperative period. Anesth Analg. 2011;112:292–318.
Hebl JR. The.importance and implications of aseptic tecniques during regional anesthesia. Reg Anesth Pain Med. 2006;31(4):311–23.
Helleberg L. Clinical pharmacocinetic of indometacin. Clin Pharmacokinet. 1981;6:245–58.
Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimes, and guidelines for regional anesthetic management. Anesth Analg. 1997;85:874–85.
Horlocker TT, Bajwa ZH, Ashraf Z, et al. Risk assessment of hemorrhagic complications associated with nonsteroidal antiinflammatory medications in ambulatory pain clinic patients undergoing epidural steroid injection. Anesth Analg. 2002;95:1691–7.
Horlocker TT, Vandermeulen E, Kopp SL, Gogarten W, Leffert L, Benzon HAT. Regional anesthesia in the patient recieving antithrombotic therapy or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence- based guide; 153:line(fourth edition). Reg Anesth Pain Med. 2018;43:263–309.
Hudson P, Gnanaseakaran S, Knowles M. Improvement of documentation of epidural insertion with the addition of a sticker to the anesthetic chart: an audit circle. Reg Anesth Pain Med. 2008;33:e34.
Jankovic D. New approaches to chronic pain: Nerve blocks in the head. In: Van Zundert A, Rawal N, editors. Highlights in regional anesthesia and pain therapy. XI (Special Edition: World Congress on Regional Anaesthesia and Pain Therapy, Barcelona); 2002. p. 258–69.
Jiang J, Hu Y, Zhang J, et al. Safety, pharmacokinetics and pharmacodynamic of single doses of rivaroxaban- an oral, direct factor Xa inhibitor-in elderly Chinese subjects. Thromb Haemost. 2010;103:234–41.
Jimenez AH, Stubbs ME, Tofler GH, et al. Rapidity and duration of platelet supression by enteric-coated aspirin in healthy young men. Am J Cardiol. 1992;69:258–62.
Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873–88.
Laux V, Perzborn E, Kubitza, et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral direct factor Xa inhibitor. Semin Thromb Hemost. 2007;33:515–23.
Leighton BL, Bauman J, Seltzer J. The effect of a detailed anesthesia consent form on patient recall and anxiety. Anesthesiology. 1987;67:A567.
Levy JH, Faraoni D, Spring JL, et al. Managing new oral anticoagulans in the perioperative and intensive care unit setting. Anesthesiology. 2013;118:1466–74.
Matthews J, Rutter S, Paul R. Standardized peripheral nerve block label can improve documentation. Reg Anesth Pain Med. 2007;32:128.
Matushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacolol Drug Dev. 2013;2:358–66.
Meisel A, Roth LH. What we do and do not know about informed consent. JAMA. 1981;246:2473–7.
Meyer RA, Campbell JN, Raja SN. Peripheral neural mechanisms of nociception. In: Wall PD, Melzack R, editors. Textbook of pain. 3rd ed. London: Churchill Livinstone; 1994. p. 13–44.
Mroszczak EJ, Jung D, Yee J, et al. Ketorolac tromethamine pharmacokinetics and metabolsm after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy. 1990;10:33S–9S.
Mulroy MF, Hejtmanek MR. Prevention of local anesthetic systemic toxicity. Reg Anesth Pain Med. 2010;35:177–80.
Narouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T, Rauck R, Huntoon MA. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications (second edition): guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2018;43(3):225–62.
Neal JM. McMahon DJ. Equipment. In Brown DL(eds): Regional anesthesia and analgesia. 1. WB Saunders Philadelphia 2005; pp 159-172
Neal MJ, Bernards MC, Butterworth FJ, Di Gregorio G, Drasner K, Hejtmanek M, Mulroy MF, Rosenquist RW, Weinberg GL. ASRA Practice Advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med. 2010;35:152–61.
Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetic of oxicam nonsteroidal anti-inflamatory agents. Clin Pharmacokinet. 1994;26:107–20.
Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetic after oral administration to humans. Drug Metab Dispos. 2009;37:74–81.
Rainsford KD. Ibuprofen:pharmacology, efficacy and safety. Inflammopharmacology. 2009;17:275–342.
Raj PP. Guidelines for regional anesthestic technique. In: Hahn MB, Mc Quillan PM, Shepöpck GJ, editors. Regional anesthesia: an atlas of anatomy and techniques. Maryland Heights: Mosby; 1996. p. 21–38.
Reitz S, Haggmark S, Johansson G, et al. Cardiotoxicity of ropivacaine- a new amide local anesthetic agent. Acta Anaesthesiol Scand. 1989;33:93–8.
Ritchie JM, Greengard P. On the mode of action of local anesthetics. Annu Rev Pharmacol. 1966;6:405–30.
Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology. 1991;41:1024–8.
Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol. 1995;37:246–53.
Rowbotham MC, Davies PS, Galer BS. Multicenter, double-blind, vehicle-controlled trial of long term use of lidocaine patches for postherpetic neuralgia (abstract). In: 8th World congress on pain. IASP Press; 1996a. p. 274.
Rowbotham MC, Davies PS, Verkempinck C. Lidocaine patch: double-blind controlled study of a new treatment method for postherpetic neuralgia. Pain. 1996b;65:39–44.
Ruff RL, Dougherty JH Jr. Complication of lumbar puncture followed by anticoagulation. Stroke. 1981;12:879–81.
Santos AC, Arthur GR, Lehning EJ, et al. Comparative pharmacokinetics of ropivacaine and bupivacaine in nonpregnant and pregnant ewes. Anesth Analg. 1997;85:87–93.
Slaughter S, et al. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin- resistant enterococci in medical intensive care unit. Ann Intern med. 1996;125(6):448–56.
Small RE. Diclofenac sodium. Clin Pharm. 1989;8:545–58.
Sonksen JR, Kong KL, Holder R. magnitude and time course of impaired primary haemostasis after stopping chronic low back and medium dose aspirin in healthy volunteers. Br J Anesth. 1999;82:360–5.
Tsui BC, Wagner A, Finucane B. Regional anesthesia in elderly: a clinical guide. Drugs Aging. 2004;21:895–910.
Tucker GT, Mather LE. Pharmacocinetics of local anesthetic agents. Br J Anesth. 1975;47:213–4.
Türc D, Roth W, Busch U. A review oft he clinical pharmacokinetics of meloxicam. Br J Rheumatol. 1996;(35 Suppl 1):13–6.
Vandermeulen EP, van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg. 1994;79:1165–77.
Von Känel R, Mills PJ, Fainman C, et al. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease? Psychosom Med. 2001;63:531–44.
Warner NS, Moeschler SM, Warner MA, et al. Bleeding complications in patients undergoing celiac plexus block. Reg Anesth Pain Med. 2016;41:488–93.
Warner NS, Bendel MA, Warner MA, et al. Bleeding complications in patients undergoing intrathecal drug delivery system implantation. Pain Med. 2017;18:2422–7.
Waurick K, Riess H, Van Acken H, Kessler P, Gogarten W, Volk T. S1-Leitlinie. Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe/antithrombotische Medikation. Anästh Intensivmed. 2014;55:464–92.
Weinberg LG. Treatment of local anesthetic systemic toxicity (LAST). Reg Anesth Pain Med. 2010;35:188–93.
Weitz JL. Drug therapy: low -molecular-weight heparins. N Engl J Med. 1997;337:688–98.
Weninger E. Pharmakodynamik der Lokalanästhetika. Anästhesiol Intensivmedizin. 1996a;5(37):249–67.
Weninger E. Pharmakodynamik der Lokalanästhetika. Anästhesiol Intensivmedizin. 1996b;5(37):249–67.
Zimmermann M. Physiologie von Nozizeption und Schmerz. In: Zimmermann M, Handwerker HO, editors. Schmerz-Konzepte und ärztliches Handeln. Berlin: Springer; 1984.
Zink W, et al. Bupivacaine but not Ropivacaine induces apoptosis in mammalian skeletal muscle fibers. Poster Discussion, Local Anesthesia and Pain, Basic Science II, ASA: A-971; 2002.
Zisman E, Erport A, Kohanovsky E, et al. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients. Eur J Anesthesiol. 2010;27:617–23.
Zwara DA, Nelson JM, Brooker RF, et al. The importance of the postoperative anesthetic visit: do repeated visits improve patient satisfaction or physitian recognition? Anesth Analg. 1996;83:793–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jankovic, D. (2022). Regional Nerve Block in Anesthesia and Pain Therapy: General Consideration. In: Jankovic, D., Peng, P. (eds) Regional Nerve Blocks in Anesthesia and Pain Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-88727-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-88727-8_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-88726-1
Online ISBN: 978-3-030-88727-8
eBook Packages: MedicineMedicine (R0)